Gaithersburg, MD – November 7, 2024 – 20/20 GeneSystems, Inc., an early market leader in multi-cancer early detection blood testing, announces that it has entered an Engagement Agreement with ClearingBid, Inc., a provider of the first platform enabling ordinary individuals and institutions to invest in IPOs at the same time, and on the same terms, […]
COVID-19 PCR TESTING Criteria for a Free Testing Due to recent changes in Federal coverage for COVID testing, certain medical necessity criteria must now be met for free testing. Check with your insurance provider to see if your test will be covered. Payment may be due at time of testing. Covid-19 Testing To register your
Portal Help Center HELP TOPICS FOR PARENTS 1. How To register your student 2. How to add a second student to your account 3. How to view test reports HELP TOPICS FOR TEACHERS 1. How to register for a teacher 2. How to view test results 3. How to change your account settings TOPICS FOR
Press 20/20 GeneSystems Enters Engagement Agreement with ClearingBid, Pioneer of the First “Crowd-Powered” Open IPOs 20/20 GeneSystems, Inc., an early market leader in multi-cancer early detection blood testing, announces that it has entered an Engagement Agreement with ClearingBid, Inc., a provider of the first platform enabling ordinary individuals and institutions to invest in IPOs at
Meet our Team Executive Management Jonathan Cohen President & CEO Mr. Cohen is the founder of our company and has served as Chief Executive Officer, President, and a director since its inception. He is a co-inventor of two of our most successful products, OneTest and BioCheck, and has led the commercial launch and sales of
Investment Information Investor Portal Please enter your details to gain access to the Investor Portal:
20/20 GeneSystems We Modernize Clinical Lab Testing with Machine Learning and Real-World Data Learn More Our Products OneTest™ for Cancer OneTest is the first test of its kind to combine the results of six cancer biomarker tests (from a single blood draw) and personal health data with an artificial intelligence algorithm to calculate a probability
Welcome to 20/20 GeneSytems Read More »
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development.
